Đang chuẩn bị liên kết để tải về tài liệu:
EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Epidermal growth factor receptor (EGFR) mutation-induced drug resistance has caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However, structural information is available for just a few EGFR mutants. |

TÀI LIỆU LIÊN QUAN

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: A retrospective, multicenter study

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: A systematic review and meta-analysis of 11 randomized controlled trials

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib

LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: A case-control observational study